Aquestive Therapeutics Reports Q3 2026 Results with Revenue Decline and Anaphylm Regulatory Update
Aquestive Therapeutics (AQST) reported third-quarter 2026 revenue of $7.6 million, a 41% decrease compared to the previous year, primarily driven by fluctuations in Suboxone product orders. The company recorded a net loss of $16.5 million ($0.13 per share), impacted by lower revenue and increased interest expenses related to debt refinancing. Despite the quarterly decline, management maintained full-year revenue guidance of $46 million to $50 million and expects year-end cash reserves to exceed $70 million. Key strategic developments include a $10 million upfront payment from Eton Pharmaceuticals for Libervant commercialization rights and an upcoming PDUFA date for Anaphylm set for March 16, 2027.
Topics: Cash guidance FDA PDUFA date Licensing agreement Net loss Revenue decline